Prostate cancer drug now available on the PBS
As from 1 November, Australian men with advanced prostate cancer can access Taxotere (docetaxel) via the Pharmaceutical Benefits Scheme (PBS).
“This is a significant day for all Australian men with prostate cancer and their families,” chief executive of the Prostate Cancer Foundation of Australia, Andrew Giles, said.
“While Taxotere has been approved for use in breast, ovarian and lung cancers, this decision means that men will now be able to access a treatment with a proven track record. The PBS listing acknowledges the importance of funding therapies for men’s health issues.”
Prostate cancer is the most common cancer in Australian men, with 18,700 diagnosed each year. It is also the second highest cause of male cancer deaths annually, killing 2,900 men each year – with eight men losing their lives to the disease each day.
Mr Giles believes the Government decision is not only welcome news for patients and their families, but is also an important opportunity to raise awareness of the importance of early detection and prevention.
“Ensuring patients have affordable access to the best available therapies is integral to managing prostate cancer in this country. However, the key to overcoming prostate cancer is early diagnosis,” Mr Giles said.
“I urge all Australian men aged 50 years and over, or with a family history of prostate cancer, to visit their doctor for a prostate check every year.”
